Key statistics
As of last trade, Cytodyn Inc (296:STU) traded at 0.116, 16.00% above the 52 week low of 0.10 set on Aug 15, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.13 |
---|---|
High | 0.13 |
Low | 0.116 |
Bid | 0.116 |
Offer | 0.126 |
Previous close | 0.12 |
Average volume | 24.69k |
---|---|
Shares outstanding | 1.22bn |
Free float | 1.21bn |
P/E (TTM) | -- |
Market cap | 152.48m USD |
EPS (TTM) | -0.0241 USD |
Data delayed at least 15 minutes, as of Nov 12 2024.
More ▼
Announcements
- CytoDyn Announces FDA Clearance of Its Phase II Oncology Trial
- CytoDyn Appoints Dr. Melissa Palmer, M.D., as Lead Consultant in Hepatology; Announces Follow-Up Inflammation Studies with SMC Laboratories
- CytoDyn Appoints Dr. Max Lataillade as Senior Vice President and Head of Clinical Development
- CytoDyn Announces Abstract that Highlights Leronlimab’s Potential in Mediating ART-Free Viral Control in Infant Rhesus Macaques
- CytoDyn Engages Syneos Health as CRO For Its Phase II Oncology Trial
- CytoDyn Announces Preliminary Findings in Study with SMC Laboratories
- September 2024 Letter to Shareholders
- CytoDyn Engages Leading CRO For Phase II Inflammation Trial
- CytoDyn Announces Completion of FDA Meeting on Phase II Study of Leronlimab in Patients with Relapsed/Refractory Microsatellite Stable Colorectal Cancer
- CytoDyn Announces Settlement with Amarex Clinical Research LLC
More ▼